PA8586201A1 - Nuevas formulaciones de liberacion prolongada inyectables - Google Patents

Nuevas formulaciones de liberacion prolongada inyectables

Info

Publication number
PA8586201A1
PA8586201A1 PA20038586201A PA8586201A PA8586201A1 PA 8586201 A1 PA8586201 A1 PA 8586201A1 PA 20038586201 A PA20038586201 A PA 20038586201A PA 8586201 A PA8586201 A PA 8586201A PA 8586201 A1 PA8586201 A1 PA 8586201A1
Authority
PA
Panama
Prior art keywords
prolonged release
release formulations
new injectable
injectable prolonged
new
Prior art date
Application number
PA20038586201A
Other languages
English (en)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8586201A1 publication Critical patent/PA8586201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

SE PROPORCIONA UNA FORMULACION DE LIBERACION PROLONGADA INYECTABLE QUE ES VISCOSA, O QUE SE HACE VISCOSA IN SITU, QUE COMPRENDE UN COMPUESTO FARMACEUTICO ARILHETEROCICLICO SOLUBILIZADO, COMO POR EJEMPLO ZIPRASIDONA.
PA20038586201A 2002-10-25 2003-10-14 Nuevas formulaciones de liberacion prolongada inyectables PA8586201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
PA8586201A1 true PA8586201A1 (es) 2004-09-16

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038586201A PA8586201A1 (es) 2002-10-25 2003-10-14 Nuevas formulaciones de liberacion prolongada inyectables

Country Status (20)

Country Link
US (1) US20040138237A1 (es)
EP (1) EP1575616A2 (es)
JP (1) JP2006514923A (es)
KR (1) KR20050055781A (es)
CN (1) CN1849110A (es)
AR (1) AR041722A1 (es)
AU (1) AU2003267788A1 (es)
BR (1) BR0315568A (es)
CA (1) CA2503076A1 (es)
MX (1) MXPA05002561A (es)
NL (1) NL1024590C2 (es)
NO (1) NO20052463L (es)
PA (1) PA8586201A1 (es)
PE (1) PE20040499A1 (es)
PL (1) PL377679A1 (es)
RU (1) RU2310450C2 (es)
TW (1) TW200423941A (es)
UY (1) UY28038A1 (es)
WO (1) WO2004037289A2 (es)
ZA (1) ZA200501921B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
JP4865330B2 (ja) 2002-12-13 2012-02-01 デュレクト コーポレーション 経口ドラッグデリバリーシステム
KR20080093464A (ko) * 2003-09-02 2008-10-21 화이자 프로덕츠 인크. 지프라시돈 나노입자
DK1809329T3 (da) 2004-09-17 2012-04-02 Durect Corp Vedvarende lokalanæstesisammensætning indeholdende saib
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP2009533314A (ja) * 2005-04-13 2009-09-17 ファイザー・プロダクツ・インク ナノ粒子を含む貧溶性薬物を持続放出するための注射用デポ製剤および方法
KR20070119678A (ko) * 2005-04-13 2007-12-20 화이자 프로덕츠 인코포레이티드 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법
CN101879140A (zh) * 2005-06-20 2010-11-10 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
NZ581862A (en) 2007-05-25 2012-06-29 Tolmar Therapeutics Inc Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient
JP2011506319A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
US20110144202A1 (en) * 2008-06-16 2011-06-16 Uwe Marx Concentrated oxaliplatin solution and its method of preparation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
MX2019012352A (es) 2018-10-15 2020-08-20 Avent Inc Composiciones, sistemas, kits y metodos para ablacion neural.
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
RU2219924C2 (ru) * 1998-04-14 2003-12-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения нейропсихиатрических расстройств
EE04704B1 (et) * 1999-05-27 2006-10-16 Pfizer Products Inc. Ziprasidooni suspensioon
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
CA2441744C (en) * 2001-03-20 2011-07-12 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Also Published As

Publication number Publication date
AU2003267788A1 (en) 2004-05-13
EP1575616A2 (en) 2005-09-21
TW200423941A (en) 2004-11-16
BR0315568A (pt) 2005-08-23
CN1849110A (zh) 2006-10-18
NO20052463L (no) 2005-05-23
MXPA05002561A (es) 2005-05-05
PE20040499A1 (es) 2004-08-18
WO2004037289A2 (en) 2004-05-06
NL1024590C2 (nl) 2005-05-23
KR20050055781A (ko) 2005-06-13
AR041722A1 (es) 2005-05-26
RU2005112207A (ru) 2005-09-10
US20040138237A1 (en) 2004-07-15
JP2006514923A (ja) 2006-05-18
RU2310450C2 (ru) 2007-11-20
WO2004037289A3 (en) 2005-12-01
CA2503076A1 (en) 2004-05-06
ZA200501921B (en) 2006-10-25
UY28038A1 (es) 2004-05-31
NL1024590A1 (nl) 2004-04-27
PL377679A1 (pl) 2006-02-06

Similar Documents

Publication Publication Date Title
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
CR8428A (es) Agente endoparasiticidas para la administracion topica
UY26496A1 (es) Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco
HN2000000267A (es) Oxazolidinonas substituidas y su uso
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
ECSP056071A (es) Nueva difenilazetidinona con características fisiológicas mejoradas, correspondiente método de producción, medicamentos que contienen dicho compuesto y su uso
ECSP066346A (es) Forma de administración a prueba de abuso
PA8554501A1 (es) Composicion fungicida basada en derivados de arilamidina y compuestos fungicos conocidos
AR047928A1 (es) Derivados de tetrahidropiridoindol
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
AR109263A2 (es) Composición que comprende moxidectina
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BRPI0511389A (pt) composição e seu uso
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
UY28715A1 (es) Derivados de diarilmetil piperazina, sus preparaciones y sus usos
AR041826A1 (es) Formulaciones de liberacion prolongada en formas de suspension
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
AR043173A1 (es) Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular